Press release
Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium
AUSTIN, Texas, Dec. 7, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, plans to present new clinical data on its
About this update from Natera, Inc.
[{"type":"text","content":"AUSTIN, Texas, Dec. 7, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, plans to present new clinical data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its hereditary cancer test, Empower, at the 2022 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.\n\n \n \n \n \n \n \n\n \nNatera will present two posters from the LEADER and I-SPY 2 clinical trials in HR+, HER2- breast cancer highlighting Signatera's ability to detect recurrence and facilitate treatment response monitoring. A third poster from a multi-center study of over 1,900 patients will describe how hereditary cancer screening with Empower at the time of imaging can help to identify patients who may benefit from cancer risk management.\n\"We are excited to share data from these studies, which provide important insights about the value of MRD testing and hereditary cancer screening across the continuum of care for patients with breast cancer,\" said Minetta Liu, M.D., chief medical officer of oncology at Natera.\nInformation on the poster presentations are as follows:\nDec. 8, 2022, 5:00 pm CST\nMonitoring for response and recurrence in neoadjuvant-treated hormone receptor-positive HER2-negative breast cancer by personalized circulating-tumor DNA testingPoster Presentation: P5-05-05 | Presenter: Magbanua MJMDec. 9, 2022, 7:00 am CST\nCell-free DNA (cfDNA) monitoring in a phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor ribociclib for localized ER+/HER2- breast cancer (LEADER)Spotlight Poster Presentation: PD17-03 | Presenter: Medford AJ Implementation and outcomes of population-based hereditary cancer testing across a diverse multi-location breast imaging centerPoster Presentation: P6-02-06 | Presenter: Miltenburg DAbout Natera\nNatera™ is a leader in personalized genetic testing and diagnostics, transforming how we make critical health care decisions. Our genetic and diagnostic tests help clinicians and their patients protect their health and enable earlier and more targeted interventions that lead to longer, healthier lives. Natera's tests are validated by more than 80 peer-reviewed studies that demonstrate high accuracy, improving patient care outcomes in oncology, women's health and organ health. Natera operates ISO 13485-certified and CAP-accr...